Earnings call transcript: Inspire Medical Systems Q2 2025 reports stock surge

Inspire Medical Systems (INSP) reported Q2 2025 revenue of $217.1 million (+11% YoY) and a 14% rise in Adjusted EBITDA, but posted a net loss and significantly lowered its full-year revenue guidance to $900-910 million and EPS to $0.40-$0.50. This downward revision stems primarily from implementation challenges with the new Inspire V system, including slow customer adoption of SleepSync and delays in Medicare billing updates. Despite these operational hurdles, INSP's stock rose 3.41% after-hours, signaling investor confidence in the Inspire V system's long-term potential, as early adopters have seen a 20% reduction in surgical times and increased implant volumes, with management forecasting accelerated growth in 2026.

Analysis

Inspire Medical Systems (INSP) reported mixed second-quarter 2025 results, characterized by solid top-line growth but significant operational challenges that prompted a sharp downward revision in full-year guidance. Revenue grew 11% year-over-year to $217.1 million, driven by a 23% increase in international sales, while adjusted EBITDA rose 14% to $44.1 million. However, the company swung to a net loss of $3.6 million from a $9.8 million profit in the prior-year period. The primary concern is the substantial reduction in full-year guidance, with revenue now projected at $900-910 million (down from $940-955 million) and EPS cut to $0.40-$0.50 (from $2.20-$2.30). Management attributed these revisions to execution headwinds with the launch of its new Inspire V system, including slower-than-expected customer implementation of the required SleepSync software and a temporary delay in Medicare's ability to process claims under the new CPT code, which has since been resolved. Despite these near-term fumbles, early data from centers using Inspire V is strong, showing a 20% increase in patient implant volumes and a 20% reduction in surgical times. The positive after-hours stock move of 3.41% suggests investors are looking past the transient execution issues, focusing instead on the system's long-term efficiency gains and management's forecast for growth to re-accelerate in 2026.

Key Decisions for Investors

• Investors should monitor management's execution on resolving the Inspire V rollout friction, particularly the rate of SleepSync adoption across centers and the impact of increased marketing spend in the second half of the year.
• The guidance cut effectively shifts the growth story to 2026, so investors must weigh the near-term volatility and execution risk against the potential for re-accelerated growth once the transition hurdles are cleared.
• Pay close attention to leading indicators in the next two quarters, such as the burn-down rate of Inspire IV inventory, the speed of new center expansion, and any further quantification of the impact from GLP-1 weight loss drugs.
• Given the stock's positive reaction to negative guidance, the market appears to be discounting the temporary setbacks; therefore, any further operational missteps could present a significant risk, while successful execution could validate the bullish long-term thesis.